Yu Zhang,Aijing Liu,Nan Jiang,Xiaole Qi,Yulong Gao,Hongyu Cui,Changjun Liu,Yanping Zhang,Kai Li,Li Gao,Xiaomei Wang,Qing Pan

Vet Microbiol.2022 Feb 17;266:109375.doi: 10.1016/j.vetmic.2022.109375. Online ahead of print.

Abstract

The emerging hepatitis-hydropericardium syndrome (HHS) caused by the novel genotype of fowl adenovirus 4 (FAdV-4) and the infectious bursal disease (IBD) caused by the infectious bursal disease virus (IBDV) are important avian diseases, both cause huge economic losses to the poultry industry. Therefore, it is necessary to develop an efficient and convenient FAdV-4/IBDV bivalent vaccine to prevent the spread of FAdV-4 and IBDV infections. Given that VP2 is the main structural protein and protective antigen of IBDV, we constructed a recombinant FAdV-4 expressing IBDV VP2 in our previous study. In the current study, an inactivated bivalent FAdV-4/IBDV vaccine was developed from the recombinant strain. The inactivated bivalent vaccine elicited effective and specific neutralizing antibodies against both FAdV-4 and IBDV in specific-pathogen-free chickens. Furthermore, the novel vaccine not only protected chickens from death caused by FAdV-4 and the very virulent IBDV (vvIBDV) infection, but also ameliorated target organ damage and reduced viral load. The FAdV-4-vectored vaccine developed in this study provides new options for the development of avian polyvalent inactivated vaccines and is a powerful tool for the prevention of both emerging HHS and IBD.

Keywords: Bivalent vaccine; Emerging HHS; FAdV-4; IBDV; Inactivated vaccine.

Copyright © 2022 Elsevier B.V. All rights reserved.